FY2019 Earnings Estimate for Antares Pharma Inc Issued By Jefferies Financial Group (NASDAQ:ATRS)

Antares Pharma Inc (NASDAQ:ATRS) – Research analysts at Jefferies Financial Group lifted their FY2019 EPS estimates for shares of Antares Pharma in a report released on Tuesday, November 5th. Jefferies Financial Group analyst A. Petrone now anticipates that the specialty pharmaceutical company will post earnings of ($0.04) per share for the year, up from their previous forecast of ($0.10). Jefferies Financial Group also issued estimates for Antares Pharma’s Q4 2019 earnings at $0.00 EPS, Q1 2020 earnings at ($0.02) EPS, Q2 2020 earnings at ($0.01) EPS, Q3 2020 earnings at $0.02 EPS, Q4 2020 earnings at $0.02 EPS, FY2020 earnings at $0.01 EPS, FY2022 earnings at $0.29 EPS and FY2023 earnings at $0.42 EPS.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.43%. The firm had revenue of $34.31 million during the quarter, compared to analysts’ expectations of $26.36 million.

Separately, BidaskClub raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 19th. One investment analyst has rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $4.05.

ATRS traded down $0.04 on Friday, reaching $3.64. The company had a trading volume of 3,597,824 shares, compared to its average volume of 1,010,181. Antares Pharma has a 1 year low of $2.53 and a 1 year high of $3.96. The stock has a market capitalization of $602.51 million, a PE ratio of -91.00 and a beta of 0.80. The company has a quick ratio of 2.87, a current ratio of 3.46 and a debt-to-equity ratio of 1.01. The stock has a 50-day moving average price of $3.45 and a 200-day moving average price of $3.17.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Antares Pharma by 10.0% in the second quarter. BlackRock Inc. now owns 10,904,306 shares of the specialty pharmaceutical company’s stock valued at $35,875,000 after purchasing an additional 993,787 shares during the period. Vanguard Group Inc. boosted its position in Antares Pharma by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 7,419,037 shares of the specialty pharmaceutical company’s stock worth $24,409,000 after acquiring an additional 110,433 shares during the last quarter. Sargent Investment Group LLC boosted its holdings in shares of Antares Pharma by 3.4% in the 3rd quarter. Sargent Investment Group LLC now owns 3,324,890 shares of the specialty pharmaceutical company’s stock valued at $11,122,000 after buying an additional 108,315 shares during the last quarter. Cortina Asset Management LLC boosted its holdings in shares of Antares Pharma by 100.3% in the 2nd quarter. Cortina Asset Management LLC now owns 2,072,605 shares of the specialty pharmaceutical company’s stock valued at $6,819,000 after buying an additional 1,037,675 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Antares Pharma by 1.7% in the 2nd quarter. Northern Trust Corp now owns 1,799,058 shares of the specialty pharmaceutical company’s stock valued at $5,918,000 after buying an additional 29,578 shares during the last quarter. Institutional investors own 38.74% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Article: The role of implied volatility with call option volume

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply